ArticleMolecular biology reports2025
Protein kinase C iota (PKCι) and pVHL are both needed for lysosomal degradation of α5 integrin in renal carcinoma cells.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics.Biomarker research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundvon Hippel-Lindau (VHL) hereditary cancer syndrome is caused by mutations in the VHL tumor suppressor gene and is characterized by a predisposition to form various types of tumors, including renal cell carcinomas, hemangioblastomas, and pheochromocytomas. The protein products of the VHL gene, pVHL, are part of an ubiquitin ligase complex that tags hypoxia inducible factor alpha (HIF-α) for proteosomal degradation. pVHL has also been reported to bind to atypical protein kinase C (aPKC). METHODS AND
resultsTo better understand the relationship between pVHL and aPKC, the PKC iota (PKCι) isoform of aPKC was knocked out in renal carcinoma cells, both pVHL-negative and those with replaced pVHL. Cellular properties associated with pVHL function were assayed. Knockout of PKCι in pVHL-expressing cells led to greater downregulation of HIF-α than seen with pVHL alone, suggesting that the presence of PKCι opposes complete regulation of HIF-α by pVHL. In contrast, absence of either pVHL or PKCι disrupted tight junction formation and led to upregulated levels of α5 integrin, both of which were phenocopied by lysosomal inhibition. LAMP1 (lysosome associated membrane protein 1), a marker for lysosomes, showed dysregulated localization and altered electrophoretic gel migration in the absence of pVHL. While the upregulated α5 integrin seen in the absence of either pVHL or PKCι loss was associated with increased cell adhesion, loss of pVHL caused increased cell motility whereas loss of PKCι decreased motility.
conclusionsThese data are consistent with a known role of PKCι in endocytosis of α5 integrin and suggest a subsequent novel role of pVHL in targeting a pool of endocytosed α5 integrin for lysosomal degradation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.